New muscle relaxant drug MTR-601 tested in humans for first time
NCT ID NCT06117020
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new oral drug called MTR-601 in 89 healthy adults to see if it is safe and how the body processes it. The drug aims to reduce muscle stiffness and spasms, which could help people with conditions like cerebral palsy, multiple sclerosis, or stroke. Since this is a first-in-human study, it only looked at safety and dosing, not yet whether it works for those diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MTR-601 (oral drug that inhibits a muscle protein to reduce spasticity)
- What this could lead to
- If successful, this could lead to a new treatment for muscle stiffness and spasms in conditions like cerebral palsy or multiple sclerosis.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, so it may not work for the intended conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Worldwide Clinical Trials
San Antonio, Texas, 78217, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Spinal zaps could reboot breathing after brain injury
- Core strength: a new hope for constipation in kids with cerebral palsy?
- Can a blood pressure pill slow MS disability?
- Can brain scans reveal hidden language struggles after stroke?
- Hidden MS progression: can brain scans and blood tests predict it?